Suchergebnisse
Can Asceniv Help ADMA Stock Combat IG Market Challenges?
ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at
ADMA Biologics Q2 Earnings Call Highlights
Key Points
- Interested in ADMA Biologics Inc? Here are five stocks we like better.
- Second-quarter revenue rose 2% to $124.4 million, driven by a 24% increase in ASCENIV sales to $102.9 million
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA Biologics, Inc. ADMA reported second-quarter 2026 earnings of 16 cents per share, which matched the Zacks Consensus Estimate and rose from 14 cents in the year-ago quarter.
Revenues grew 2.0%
Gensight Biologics SA
WKN: A2ANGZ / Name: Gensight / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Innovent Biologics, Inc.
WKN: A2N7N8 / Name: Innovent Biologics / Aktie / Small Cap /
Heat Biologics Inc.
WKN: A2QJR8 / Symbol: HBTX / Name: Heat Biologics / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
Wuxi Biologics (cayman) Inc.
WKN: A2PQ3Q / Name: Wuxi Biologics (cayman) Inc. / Aktie / ? /
Synthetic Biologics Inc.
WKN: A3DMG6 / Symbol: SYN / Name: Synthetic Biologics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /